[Chinese experts consensus on the diagnosis and management of checkpoint inhibitor pneumonitis(2025)].

Checkpoint inhibitor pneumonitis (CIP) is a rare type of immune-related adverse reaction, that can seriously affect the subsequent anti-tumor immunotherapy and even lead to respiratory failure or death. However, if identified and diagnosed early, and treated promptly and appropriately, most patients have a good prognosis, and some may be eligible for subsequent immune rechallenge. In order to standardize diagnosis and treatment of patients with CIP and improve their prognosis, the Department of Pulmonary and Critical Care Medicine of Peking Union Medical College Hospital initiated and developed the consensus, which was discussed and reached a consensus by experts from the Oncology Respiratory Disease Committee of China Anti-Cancer Association, Lung Cancer Group of Thoracic Society of Chinese Medical Association and Beijing Cancer Prevention and Treatment Research Association. The consensus formed 18 expert recommendations on the risk factors, clinical characteristics, diagnostic evaluation measures, diagnostic criteria, differential diagnosis, treatment strategies and rehabilitation plans of CIP for clinicians' reference.